Immune checkpoint inhibitors in pancreatic cancer / 中华内分泌外科杂志
Chinese Journal of Endocrine Surgery
;
(6): 441-444, 2019.
Artigo
em Chinês
| WPRIM
| ID: wpr-823636
ABSTRACT
The comprehensive and multiple disciplinary team therapeutic strategies of pancreatic cancer have been accepted as a consensus. Immune checkpoint inhibitors have made great breakthroughs in the treat-ment of various solid tumors. However, immune checkpoint inhibitors failed to elicit efficacy in patients with pan-creatic cancer and how to overcome the immunosuppressive tumor microenvironment may be the crucial event. Combination regimens of immune checkpoint inhibitors with chemotherapy, radiotherapy, and molecular targeted therapy have been underway, but the sample size of the clinical trial was still limited. Considering the current re-search status and progress of pancreatic cancer, this article further discusses the practical problems of immune checkpoint inhibitors and makes objective evaluation of its value.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Journal of Endocrine Surgery
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS